Strontium ranelate causes osteophytes overgrowth in a model of early phase osteoarthritis
详细信息 查看全文
- 作者：Jian-Guo Chu ; Mu-Wei Dai ; Yu Wang ; Fa-Ming Tian…
- 关键词：Osteoarthritis ; Strontium ranelate ; Cartilage ; Osteophytes ; Subchondral bone ; Micro ; CT
- 刊名：BMC Musculoskeletal Disorders
- 出版年：2017
- 出版时间：December 2017
- 年：2017
- 卷：18
- 期：1
- 全文大小：8835KB
- 刊物主题：Orthopedics; Rehabilitation; Rheumatology; Sports Medicine; Internal Medicine; Epidemiology;
- 出版者：BioMed Central
- ISSN：1471-2474
- 卷排序：18
文摘
BackgroundOsteoarthritis (OA) involves cartilage changes as well as modifications of subchondral bone and synovial tissues. Strontium ranelate (SR), an anti-osteoporosis compound, which is currently in phase III clinical trial for treatment of OA. Evidences suggest that SR preferably deposited in osteophyte, other than in subchondral bone in early phase of OA. This phenomenon raises concern about its utility for OA treatment as a disease-modifying drug. To evaluate the effect of SR on cartilage, subchondral bone mass and subchondral trabecular bone structure in medial meniscectomized (MNX) guinea pigs.